

Table S1: Characteristics of Included Studies

Study	Design/setting	Sample	Strategies	Assumptions	Main findings
Effectiveness					
Emery et al [44]	<ul style="list-style-type: none"> Modeling study in Japan 	<ul style="list-style-type: none"> 3711 	<ul style="list-style-type: none"> Symptom-based testing Symptom-agnostic testing 	<ul style="list-style-type: none"> Constant infectiousness Progress to presymptomatic/asymptomatic is irrespective of the origin of infections. Unavailable symptom onset date for 115 cases proportional to cases with reported dates Unavailable test dates for 13 persons proportionate to tests among those with unreported symptom onset. Proportion of asymptomatic infectiousness Individual test negative after the infectious period Test accuracy = 100% People are 50% more likely to be tested in biased symptom-agnostic testing 	<ul style="list-style-type: none"> Testing irrespective of symptoms showed to be more effective in case identification than symptom-based testing
Grassly et al [45]	<ul style="list-style-type: none"> Modeling study in the UK 	<ul style="list-style-type: none"> Hypothetical 	<ul style="list-style-type: none"> Symptom-based self-isolation Symptom testing and case isolation. 	<ul style="list-style-type: none"> Asymptomatic individuals are less infectious than symptomatic individuals. 100% Polymerase chain 	<ul style="list-style-type: none"> Self-isolation upon symptom onset will reduce transmissions by 47% (95% Uncertainty)

Study	Design/ setting	Sample	Strategies	Assumptions	Main findings
			<ul style="list-style-type: none"> Regular testing of high-risk groups irrespective of symptoms & isolation Test and trace of contacts & isolation Contact tracing by symptoms alone. Test-trace-test contacts and isolate 	<ul style="list-style-type: none"> reaction (PCR) test sensitivity 100% coverage of Test and Trace Sample collection is done at symptom onset. 1 day delay from sample collection and quarantining of contacts. 80% of symptomatic cases are reported. 80% of symptomatic contacts are traced. Testing is done on the day of symptom onset 	<ul style="list-style-type: none"> Interval, UI: 32-55). Screening all healthcare workers and other high at-risk populations every week will further reduce transmission by 23% (95% Uncertainty Interval: UI 16–40) in addition to that achieved by isolation. Test and trace will further reduce transmissions by 26% (95% UI:14-35)
Tsou et al [46]	<ul style="list-style-type: none"> Modeling study in Taiwan 	<ul style="list-style-type: none"> 393 	<ul style="list-style-type: none"> Symptom-based testing and isolation of index cases Mass testing of symptomatic and asymptomatic subclinical cases Symptom-based testing, isolation, and quarantine of all at-risk group 	<ul style="list-style-type: none"> Incubation period per case and symptom onset to isolation delay, follow a Weibull distribution. Potential secondary cases follow a negative binomial distribution with mean = reproduction number R Strategies differed in their control of subclinical cases. Initial number of cases = 5, 20 & 40 At-risk persons investigated = 40%, 60%, 80% & 90% 	<ul style="list-style-type: none"> The strategy of symptom-based testing, isolation, and quarantining all subclinical cases was most effective. Strategy B was better than A in the prevention of transmissions before symptom onset

Study	Design/ setting	Sample	Strategies	Assumptions	Main findings
				<ul style="list-style-type: none"> • 40%, 60%, 80% of subclinical cases assumed to be detected and isolated. • Subclinical cases can completely be prevented 	
Mizumoto et al [47]	<ul style="list-style-type: none"> • Modeling study in Japan 	<ul style="list-style-type: none"> • 3063 	<ul style="list-style-type: none"> • Mass testing 	N/A	<ul style="list-style-type: none"> • A total of 634 cases were detected 328 of whom were asymptomatic. • The proportion of asymptomatic increased over the weeks
Sasmita et al [48]	<ul style="list-style-type: none"> • Modeling study in Indonesia 	<ul style="list-style-type: none"> • Daily Covid-19 cases 	<ul style="list-style-type: none"> • Scenario 1 = $u1+u4+u5$ • Scenario 2 = $u1+u2+u4+u5$ • Scenario 3 = $u1+u2+u3+u4+u5$ • U1 = Large-scale social restriction; U2 = Contact tracing; U3 = Mass testing; U4 = Case detection and treatment; U5 = Face masks use 	<ul style="list-style-type: none"> • 95% false positive rate from susceptible to exposed. • Possibility of reinfections due to loss of immunity • All parameters were assumed to be positive and constant. • Availability of rapid PCR tests 	<ul style="list-style-type: none"> • COVID-19 cases attained peak for strategy 1, 2, and 3 on 59th, 38th, and 40th day after initial outbreak with 33151, 37908, and 39305 cases, respectively. • The optimal control measure was scenario 2 with (u1), (u2), (u4), and (u5)
Moghadass et al [49]	<ul style="list-style-type: none"> • Modeling study in Canada 	<ul style="list-style-type: none"> • Hypothetical 	<ul style="list-style-type: none"> • No self-isolation • 100% severe cases self-isolate • 100% symptomatic 	<ul style="list-style-type: none"> • The Proportion of asymptomatic infections is 17.9% and 30.8% 	<ul style="list-style-type: none"> • Isolating all symptomatic will still be inefficient in outbreak control. • Combined with case

Study	Design/ setting	Sample	Strategies	Assumptions	Main findings
			<ul style="list-style-type: none"> case self-isolate 100% isolation of symptomatic cases plus detection and isolation of asymptomatic cases 		isolation, results indicated that 33% and 42% detection and isolation of silent infections would be needed to suppress the attack rate below 1%, for asymptomatic proportions of 17.9% and 30.8%, respectively
Bracis et al [50]	<ul style="list-style-type: none"> Modeling study in the USA 	<ul style="list-style-type: none"> Daily Covid-19 cases 	<ul style="list-style-type: none"> No intervention Isolating the elderly Schools opening in fall. Testing, treatment, isolation, and contact tracing in combination with physical distancing 	<ul style="list-style-type: none"> 20% of infections are symptomatic. Homogenous infectivity and outcome Constant diagnostic rate More than 40% diagnosed during early testing. 50% of contacts are successfully traced. Contact tracing permits 5% of asymptomatic and subclinical to be tested. Differential post-COVID-19 physical interaction 	<ul style="list-style-type: none"> Ramping up testing, isolation, and contact tracing of symptomatic cases reduced post-COVID interactions by 60% and very few deaths. Mass testing was not found to be feasible
Pollmann et al [51]	<ul style="list-style-type: none"> Modeling study 	<ul style="list-style-type: none"> Hypothetical 	<ul style="list-style-type: none"> Digital contact tracing (based on reported symptoms), Quarantining, 	<ul style="list-style-type: none"> All contacts using digital contact tracing can be traced. Unreported symptoms and untested symptomatic cases Tracing of infected contacts 	<ul style="list-style-type: none"> Contact tracing must be combined with either random mass testing or social distancing to control the epidemic.

Study	Design/ setting	Sample	Strategies	Assumptions	Main findings
			<ul style="list-style-type: none"> • Testing • Social distancing • Random testing 	<ul style="list-style-type: none"> • Immediate quarantine upon the report of symptoms • 100% test accuracy • Homogeneous population • Immunity once recovered. • No symptoms-testing delay • Absence of manual tracing • Fixed latent period. • A backward/forward tracing 	<ul style="list-style-type: none"> • Daily random testing of 20% of the population found to be as effective as social distancing
Hill et al [52]	<ul style="list-style-type: none"> • Modeling study in the UK 	<ul style="list-style-type: none"> • 2010 social contact data 	<ul style="list-style-type: none"> • Test and trace • Regular mass testing 	<ul style="list-style-type: none"> • Each person can be infectious. • Contact network follows the Poisson distribution. • Contact probabilities fall with the level of accommodation. • No random accommodation • People can infect 1-day post symptom onset. • 100% test specificity • Possible to Forget contacts • Self-isolation time=10 days • Test- results delay= 2 days • Contact isolation = 14 days • Adherence to test and trace. • No contacts during isolation • No COVID-19 student beginning the term 	<ul style="list-style-type: none"> • Daily and weekly testing combined with contact tracing adherence reduced the number of infections by more than 50% compared to test and trace alone
Gorji	<ul style="list-style-type: none"> • Modeli 	<ul style="list-style-type: none"> • Hypo 	<ul style="list-style-type: none"> • Mass testing 	<ul style="list-style-type: none"> • 90% infection reduction due to 	<ul style="list-style-type: none"> • Testing high-risk

Study	Design/setting	Sample	Strategies	Assumptions	Main findings
et al [53]	ng study in Switzerland	thetic al	<ul style="list-style-type: none"> • Contact tracing. • Smart testing^a and contact tracing 	<ul style="list-style-type: none"> • self-isolation • Basic reproduction number of 2.4 if no mitigation • Test results take 1 day. • Children under 10 contribute little to infections. • The at-risk subpopulation has a 27-fold prevalence rate. • Detection of high contact individuals every 7 days 	<ul style="list-style-type: none"> • individuals irrespective of symptoms with contact tracing will reduce R to 1. • Contact tracing based on symptom testing will miss most cases.
Alsing et al [54]	<ul style="list-style-type: none"> • Modeli ng study in the UK 	<ul style="list-style-type: none"> • 2011 com puter data and BBC pande mic datas et 	<ul style="list-style-type: none"> • Contact tracing and social distancing. • Contact tracing with Mass testing. • Contact tracing with lockdowns 	<ul style="list-style-type: none"> • Active infections at 8 months • The number of daily tests required. • Effective reproduction number (RE) per scenario • Number of people in lockdown 	<ul style="list-style-type: none"> • Possible to control 38% of outbreak simulations within 8 months using contact tracing with 63.3% of outbreak still leaving $R > 1$. • Mass testing and contact tracing contained 74% of the outbreak simulations with 36.8% of outbreaks resulting in $R < 1$
Hagan et al [55]	<ul style="list-style-type: none"> • Cross section al in the USA 	<ul style="list-style-type: none"> • 1616 1 	<ul style="list-style-type: none"> • Symptom-based testing • Mass testing 	N/A	<ul style="list-style-type: none"> • Mass testing increased the number of COVID-19 cases from 642 (range = 2–181, median = 19) after symptom-based testing to 8,239 (range = 10–2,193, median = 403) giving a

Study	Design/ setting	Sample	Strategies	Assumptions	Main findings
					median increase of 12.3-fold
Cost-Effectiveness (model)					
Paltiel et al [56]	<ul style="list-style-type: none"> Modeling study in the USA 	<ul style="list-style-type: none"> 4990 hypothetical cohort 	<ul style="list-style-type: none"> Base case scenario with a reproduction number (Rt) of 2.5, test specificity of 98%, and 10 new infections each week Worst case scenario with an Rt of 3.5, test specificity of 98%, and 25 new infections every week Best case scenario with an Rt of 1.5, test specificity of 99.7%, and 5 new infections each week 	<ul style="list-style-type: none"> Test frequency = 1, 2, 3 & 7 Test sensitivity = 70% - 99% Importation of infections via exogenous shocks Specificity of 98% - 99% Reproduction number = 1.5, 2.5 and 3.5 Case fatality = 0.05% 30% chance that infection will lead to virus symptoms. Cost per test = \$10 - \$50 Abbreviated 80-days period. A cohort of non-immune students in a congregate setting of 5,000 students 8-hour test turnaround time Availability of 100% confirmatory tests at \$100 25 new cases per week 	<ul style="list-style-type: none"> A willingness-to-pay of \leq\$5,500/infection averted, screening every week using a 70% sensitive test was optimal. Regular screening (7, 3 & 2 days) was optimal if only a single test of \$25 with 80% sensitivity was available. There was no condition under which symptom-based screening alone will contain the outbreak
Asymptomatic proportion					
Porru et al [57]	<ul style="list-style-type: none"> Cohort study in Italy 	<ul style="list-style-type: none"> 5942 	<ul style="list-style-type: none"> Mass RT-PCR^b testing using oropharyngeal and 	<ul style="list-style-type: none"> N/A 	<ul style="list-style-type: none"> A total of 238 cases were detected, of whom 109 were asymptomatic.

Study	Design/ setting	Sample	Strategies	Assumptions	Main findings
			nasopharyngeal swabs		<ul style="list-style-type: none"> • Mass testing permitted prompt isolation and monitoring of cases
Nishiura et al [58]	<ul style="list-style-type: none"> • Cross-sectional in Japan 	<ul style="list-style-type: none"> • 565 	<ul style="list-style-type: none"> • RT-PCR testing 	<ul style="list-style-type: none"> • N/A 	<ul style="list-style-type: none"> • 63 passengers were symptomatic. • Four (30.8%, 95% CI: 7.7–53.8%) of 13 positive cases were asymptomatic and 9 were symptomatic
Treibel et al [59]	<ul style="list-style-type: none"> • Cross-sectional in the UK 	<ul style="list-style-type: none"> • 396 • 284 • 263 • 267 • 269 	<ul style="list-style-type: none"> • PCR test on 400 nasopharyngeal swabs at 5-time points 	<ul style="list-style-type: none"> • N/A 	<ul style="list-style-type: none"> • Twelve (27%) of 44 positive cases were asymptomatic. • Positive. Fifty staff self-isolated as a result of symptoms
Abeyuriya et al [60]	<ul style="list-style-type: none"> • Cross-sectional in the UK 	<ul style="list-style-type: none"> • 180 	<ul style="list-style-type: none"> • Nasopharyngeal swap PCR test 	<ul style="list-style-type: none"> • N/A 	<ul style="list-style-type: none"> • Seven women tested positive with 6 (85.7%, 95% CI: 42.1–99.6) as asymptomatic. • Symptom-based testing sensitivity was 14.3% (0.36–57.87) and specificity was 91.86% (86.72–95.48)
Brown et al [61]	<ul style="list-style-type: none"> • Cross-sectional in the UK 	<ul style="list-style-type: none"> • 1152 	<ul style="list-style-type: none"> • Nasopharyngeal/oropharyngeal swap PCR tests 	<ul style="list-style-type: none"> • N/A 	<ul style="list-style-type: none"> • Thirteen (57%) of 23 positive cases had symptoms compliant with COVID-19, of whom 4

Study	Design/ setting	Sample	Strategies	Assumptions	Main findings
					(17.4%) were asymptomatic
Graham et al [62]	<ul style="list-style-type: none"> Cross-sectional in the UK 	<ul style="list-style-type: none"> 383 	<ul style="list-style-type: none"> Comprehensive testing with oropharyngeal and nasopharyngeal swabs Symptom screening 	<ul style="list-style-type: none"> N/A 	<ul style="list-style-type: none"> 126 (40%, 95% CI 35 to 46) of the 313 tested residents were positive. Only 72 (57%, 95% CI 49–66) positive cases would have been diagnosed based on symptom-testing
Arons et al [63]	<ul style="list-style-type: none"> Cross-sectional in the USA 	<ul style="list-style-type: none"> 76 	<ul style="list-style-type: none"> Point prevalence testing with RT-PCR on nasopharyngeal and oropharyngeal swabs 	<ul style="list-style-type: none"> N/A 	<ul style="list-style-type: none"> 48 (63%) of 76 tested residents were positive of whom 27 (56%) were asymptomatic. 24 of the 27 developed symptoms 1-week post-test
Jameson et al [64]	<ul style="list-style-type: none"> Cross-sectional in the USA 	<ul style="list-style-type: none"> 121 	<ul style="list-style-type: none"> Universal testing Universal symptom: screening Isolation of cases (nasopharyngeal swabs) 	<ul style="list-style-type: none"> N/A 	<ul style="list-style-type: none"> No positive case was found among 121 out of 499 eligible healthcare workers screened
Callaghan et al [65]	<ul style="list-style-type: none"> Cross-sectional in the USA 	<ul style="list-style-type: none"> 217 	<ul style="list-style-type: none"> Nasopharyngeal swap PCR test 	<ul style="list-style-type: none"> N/A 	<ul style="list-style-type: none"> No participant tested positive for COVID-19
Louie et al [66]	<ul style="list-style-type: none"> Cross-sectional in the 	<ul style="list-style-type: none"> 303 	<ul style="list-style-type: none"> Outbreak response mass testing with PCR on 	<ul style="list-style-type: none"> N/A 	<ul style="list-style-type: none"> Mass testing identified a high proportion of asymptomatic cases.

Study	Design/ setting	Sample	Strategies	Assumptions	Main findings
	USA		nasopharyngeal swabs		<ul style="list-style-type: none"> The symptom-based screening was ineffective in detecting cases among healthcare workers
Gudbjartsson et al [67]	<ul style="list-style-type: none"> Cross-sectional in Iceland 	<ul style="list-style-type: none"> 9199 10797 2283 	<ul style="list-style-type: none"> Targeted testing Open invitation screening Random invitation screening (on nasopharyngeal and oropharyngeal samples) 	<ul style="list-style-type: none"> N/A 	<ul style="list-style-type: none"> 13.3% tested positive in targeted testing, 0.8% in open invitation testing, and 0.6% in random invitation testing.
Reid et al [68]	<ul style="list-style-type: none"> Cross-sectional in Canada 	<ul style="list-style-type: none"> 2751 	<ul style="list-style-type: none"> Symptomatic testing Asymptomatic testing (on nasopharyngeal swabs) 	<ul style="list-style-type: none"> N/A 	<ul style="list-style-type: none"> 188 (6.4%) positive cases detected during symptomatic testing and 5 (0.2%) positive cases during asymptomatic testing, with a low probability of testing positive
Lavezzo et al [69]	<ul style="list-style-type: none"> Cross-sectional in Italy 	<ul style="list-style-type: none"> 2812 2343 	<ul style="list-style-type: none"> Pre and post-RT-PCR on nasopharyngeal swabs 	<ul style="list-style-type: none"> N/A 	<ul style="list-style-type: none"> The first survey gave a prevalence of 2.6% (95% CI: 2.1–3.3%) and 1.2% (95% CI: 0.8–1.8%) for survey 2. 29 (39.7%; 95% CI: 28.5–51.9%) of positive tests in the survey 1 were asymptomatic and 13 (44.8%; 95% CI: 26.5–

Study	Design/ setting	Sample	Strategies	Assumptions	Main findings
					64.3%) in survey 2.
Kimball et al [70]	<ul style="list-style-type: none"> Cross-sectional in the USA 	<ul style="list-style-type: none"> 76 	<ul style="list-style-type: none"> RT-PCR mass testing on nasopharyngeal and oropharyngeal swabs 	<ul style="list-style-type: none"> N/A 	<ul style="list-style-type: none"> Twenty-three (30%) residents were positive with 13 (57%) either presymptomatic or asymptomatic. Testing based on symptom screening could miss up to 50% of cases
Olalla et al [71]	<ul style="list-style-type: none"> Cross-sectional in Spain 	<ul style="list-style-type: none"> 498 	<ul style="list-style-type: none"> Symptom screening Asymptomatic testing (on nasopharyngeal and oropharyngeal swaps) 	<ul style="list-style-type: none"> N/A 	<ul style="list-style-type: none"> 2 asymptomatic on day of sampling tested positive. 1 reported having had symptoms in the last 14 days
Guery et al [72]	<ul style="list-style-type: none"> Cross-sectional in France 	<ul style="list-style-type: none"> 136 	<ul style="list-style-type: none"> RT-PCR mass testing on nasopharyngeal swap 	<ul style="list-style-type: none"> N/A 	<ul style="list-style-type: none"> Three (2.2%) cases detected, 1 of whom was symptomatic and the other developed symptoms within 24 hours
Roxby et al [73]	<ul style="list-style-type: none"> Cross-sectional in the USA 	<ul style="list-style-type: none"> 142 80 	<ul style="list-style-type: none"> Repeated RT-PCR mass testing on nasopharyngeal swap (7 days apart) 	<ul style="list-style-type: none"> N/A 	<ul style="list-style-type: none"> Five (7%) cases were detected, 3 of which were asymptomatic. Symptom-based testing might not identify all positive cases
Lytras et al(a) [74]	<ul style="list-style-type: none"> Cross-sectional in 	<ul style="list-style-type: none"> 357 	<ul style="list-style-type: none"> RT-PCR mass testing using nasopharyngeal 	<ul style="list-style-type: none"> N/A 	<ul style="list-style-type: none"> Thirteen (3.6%, CI: 2.0–6.1) positive asymptomatic cases

Study	Design/ setting	Sample	Strategies	Assumptions	Main findings
	Greece		swap		
Lytras et al(b) [74]	• Cross-sectional in Greece	• 394	• RT-PCR mass testing on nasopharyngeal swaps	• N/A	• Twenty-five (6.3%, 95% CI: 4.1–9.2%) positive asymptomatic cases
Lytras et al(c) [74]	• Cross-sectional in Greece	• 32	• RT-PCR mass testing on nasopharyngeal swap	• N/A	• Two (6.3%, 95% CI: 0.8–20.8%) positive asymptomatic cases
Hoehl et al [75]	• Cross-sectional in Germany	• 114	• RT-PCR mass testing on nasopharyngeal swap and sputum	• N/A	<ul style="list-style-type: none"> • Two (1.8%) of 114 asymptomatic passengers tested positive. All 11 symptomatic patients tested negative. • Symptom-based testing failed to detect SARS-CoV-2 patients.
Cao et al [76]	• Cross-sectional in China	• 9,899,828	• Citywide mass testing using TR-PCR on nasopharyngeal and throat swabs	• N/A	• No symptomatic case was found compared to 300 asymptomatic cases (0.303/10,000, 95% CI; 0.270–0.339/10,000)
Baggett et al [77]	• Cross-sectional in the USA	• 408	• Mass testing • Symptom screening (on nasopharyngeal swaps)	• N/A	• 147 (36.0%) subjects tested positive, of whom 87.8% were asymptomatic
Imbert et al	• Cross-section	• 210	• Mass RT-PCR testing on	• N/A	• Fifty-two (52%) of tested residents were

Study	Design/ setting	Sample	Strategies	Assumptions	Main findings
[78]	al in the USA		nasopharyngeal specimens		asymptomatic. This occurred when registered incidence was 5.1 case per 100,000

^aMass testing of individuals with high contact rates (at-risk group)

^bReverse transcription-polymerase chain reaction